COVID-19 Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D04FOP
|
|||
Drug Name |
Ravulizumab
|
|||
Synonyms |
Ultomiris (TN); Ravulizumab (USAN); Ravulizumab (genetical recombination) (JAN); D11054; 1803171-55-2
|
|||
Drug Type |
Monoclonal antibody
|
|||
Indication | Coronavirus Disease 2019 (COVID-19) | Phase 3 | [1] | |
Other Indication | Paroxysmal nocturnal haemoglobinuria | Approved | [2] | |
Therapeutic Class |
Antiviral Agents
|
|||
PubChem Substance ID |
Target | Top | |||
---|---|---|---|---|
Target(s) | HUMAN complement C5 protein (C5) | Target Info | Inhibitor | [3], [4] |
Inhibition of complement C5 by eculizumab can be a promising treatment for severe COVID19 by reducing the innate immune-mediated consequences of severe coronavirus infection, and can pair well with direct anti-viral therapy. |
References | Top | |||
---|---|---|---|---|
1 | ClinicalTrials.gov (NCT04369469) Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia. U.S. National Institutes of Health. | |||
2 | FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (BLA) 761108. | |||
3 | Complement as a target in COVID-19 Nat Rev Immunol. 2020 Apr 23. | |||
4 | ULTOMIRIS (ravulizumab cwvz) |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.